New hope for advanced colon cancer: drug combo trial launches

NCT ID NCT07042685

Recruiting now Disease control Sponsor: The Methodist Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase II trial is testing a combination of the targeted drug fruquintinib with standard chemotherapy as a first treatment for people with advanced colorectal cancer that cannot be removed by surgery or has spread. Fifty participants will receive the drugs in 28-day cycles, with the goal of seeing how long the cancer stays under control. The study is currently recruiting at Houston Methodist hospitals.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fruquintinib combined with 5-fluorouracil-based chemotherapy (FOLFIRI or mFOLFOX6)
What this could lead to: If successful, this could offer a new first-line treatment option for people with advanced colorectal cancer, potentially slowing disease progression.
What could go wrong: This is an early Phase II trial with only 50 participants, so results may not apply to everyone. Side effects from the drug combination could be significant, and the treatment may not work better than existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER (CRC)

Contacts and locations

Locations

Houston Methodist Neal Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.